MNKD analyst estimates
MannKind (MNKD) analyst ratings, the average price target and its range, and every firm's latest call.
MNKD analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 19, 2026 | Chardan Capital | MannKind initiated with a Buy at Chardan | $10.00 |
| Aug 6, 2026 | Wells Fargo | MannKind price target lowered to $13 from $14 at Wells Fargo | $13.00 |
| Jul 30, 2026 | Wells Fargo | MannKind price target raised to $14 from $11 at Wells Fargo | $14.00 |
| Jun 1, 2026 | Wells Fargo | MannKind price target raised to $11 from $10 at Wells Fargo | $11.00 |
| May 7, 2026 | H.C. Wainwright | MannKind price target raised to $10 from $8 at H.C. Wainwright | $10.00 |
| May 7, 2026 | Wells Fargo | MannKind price target raised to $10 from $8 at Wells Fargo | $10.00 |
| May 7, 2026 | Mizuho Securities | MannKind price target lowered to $7 from $8 at Mizuho | $7.00 |
| Apr 13, 2026 | Mizuho Securities | MannKind price target lowered to $8 from $10 at Mizuho | $8.00 |
| Apr 8, 2026 | Truist Financial | MannKind price target lowered to $6 from $7 at Truist | $6.00 |
| Nov 24, 2025 | Truist Financial | MannKind initiated with a Buy at Truist | $9.00 |
| Sep 2, 2025 | H.C. Wainwright | MannKind price target raised to $11 from $9 at H.C. Wainwright | $11.00 |
| Aug 26, 2025 | RBC Capital | MannKind price target raised to $8 from $7 at RBC Capital | $8.00 |
| Aug 25, 2025 | H.C. Wainwright | H.C. Wainwright positive on MannKind deal for scPharmaceuticals | $9.00 |
| Aug 28, 2024 | Oppenheimer | MannKind price target raised to $12 from $10 at Oppenheimer | $12.00 |
| Oct 10, 2023 | Wedbush | MannKind Analyst Turns Bullish, Says 'Don't Call It Comeback' | $10.00 |
- 8 firms rate MNKD: 7 buy, 1 hold, 0 sell.
- The average price target is $10.00 from 4 analysts, from $7.00 to $13.00.
Updated 2026-11-03 11:31 UTC